Loading
A phase 1/2 trial of Ris-Rez in sarcomas, run by GlaxoSmithKline, now recruiting.
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) is a phase 1/2 interventional study registered as NCT07602777 by GlaxoSmithKline, with 113 participants planned, started 2026-06-22 and due to reach its primary completion in 2027-11-18. Interventions recorded: Ris-Rez and G-CSF.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/